A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT07503340 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing-remitting Multiple Sclerosis

Interventions

DRUG: Ocrelizumab co-formulated with rHuPH20

Sponsor

Hoffmann-La Roche